Chemistry:Fabimycin
| |
| Names | |
|---|---|
| IUPAC name
(E)-3-(7-amino-8-oxo-5,6,7,9-tetrahydropyrido[2,3-b]azepin-3-yl)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| |
| |
| Properties | |
| C23H24N4O3 | |
| Molar mass | 404.470 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Fabimycin is an newly developed antibiotic candidate which is effective against gram-negative bacterias, an unusually problematic class of bacteria that uses thicker cell walls and molecular efflux pumps to protect themselves by preventing the antibiotics reaching inside the cells.[1][2]
Antibiotic resistance
Global deaths attributable to antimicrobial resistance (AMR) numbered 1.27 million in 2019. That year, AMR may have contributed to 5 million deaths and one in five people who died due to AMR were children under five years old.[3] The European Centre for Disease Prevention and Control calculated that in 2015 there were 671,689 infections in the EU and European Economic Area caused by antibiotic-resistant bacteria, resulting in 33,110 deaths. Most were acquired in healthcare settings.[4]
History
Researchers modified the structure of Debio-1452,[5] an under-development antibiotic that is active against gram positive bacteria, and its derivative, which is moderately effective against non-resistant gram-negative bacteria.[1][6] The drug inhibits the bacterial enzyme FabI, which is an important enzyme in bacterial fatty acid biosynthesis. Clinical trials targeting the enzyme for use in S. aureus (Gram +ve) infections have reached Phase 2 inhibitors.[2]
Fabimycin was tested in mice against more than 200 colonies of resistant bacteria, across 54 strains of E. coli, Klebsiella pneumoniae and Acinetobacter baumannii. It cleared up pneumonia and urinary tract infections, pushing bacteria levels lower than before infection in mouse models.[1]
Further, it did not affect some types of commensal bacteria present in the gut microbiome.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 Irving, Michael (2022-08-11). "New antibiotic molecule kills dozens of the toughest types of superbugs" (in en-US). https://newatlas.com/medical/new-antibiotic-molecule-toughest-superbugs/.
- ↑ 2.0 2.1 Parker, Erica N.; Cain, Brett N.; Hajian, Behnoush; Ulrich, Rebecca J.; Geddes, Emily J.; Barkho, Sulyman; Lee, Hyang Yeon; Williams, John D. et al. (2022-08-10). "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections" (in en). ACS Central Science 8 (8): 1145–1158. doi:10.1021/acscentsci.2c00598. ISSN 2374-7943. PMID 36032774.
- ↑ Murray, Christopher JL; Ikuta, Kevin Shunji; Sharara, Fablina; Swetschinski, Lucien; Aguilar, Gisela Robles; Gray, Authia; Han, Chieh; Bisignano, Catherine et al. (2022-01-19). "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis" (in English). The Lancet 399 (10325): 629–655. doi:10.1016/S0140-6736(21)02724-0. ISSN 0140-6736. PMID 35065702.
- ↑ "Antibiotic-resistant bacteria responsible for over 33,000 deaths in Europe in 2015, study finds". Pharmaceutical Journal. 7 November 2018. https://www.pharmaceutical-journal.com/20205705.article.
- ↑ Flamm, Robert K.; Rhomberg, Paul R.; Kaplan, Nachum; Jones, Ronald N.; Farrell, David J. (May 2015). "Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains". Antimicrobial Agents and Chemotherapy 59 (5): 2583–2587. doi:10.1128/AAC.05119-14. ISSN 1098-6596. PMID 25691627.
- ↑ Davis, Joe (2022-08-11). "Antibiotic-resistant bacteria: New drug can fight off 300 different types of superbugs" (in en-US). https://timetotimes.com/?p=98482.
attribution This page contains text copyrighted with a CC-BY-4.0 license from European Centre for Disease Prevention and Control
 |  |
